Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients

BACKGROUND. Brentuximab vedotin (BV) has shown high overall response rate in refractory/relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL) with reported long-term response duration in clinical trials, but few data are available regarding its role in long-term outcomes...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncologist
Egile Nagusiak: Gandolfi, Letizia, Pellegrini, Cinzia, Casadei, Beatrice, Stefoni, Vittorio, Broccoli, Alessandro, Tonialini, Lorenzo, Morigi, Alice, Argnani, Lisa, Zinzani, Pier Luigi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AlphaMed Press 2016
Gaiak:
Hematologic Malignancies
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5153337/
https://ncbi.nlm.nih.gov/pubmed/27486201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0112
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak